Top Markets
#1 Nesa Nesa +797.03%
#2 Cortex Cortex +68.91%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.76%
#4 QuantixAI QuantixAI +40.81%
#5 Pons Pons +25.08%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +20.00%
#8 Renzo Restaked LST Renzo Restaked LST +10.38%
#9 Fartcoin Fartcoin +9.77%
#10 PondCoin PondCoin +8.97%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Rank in Stocks #19723
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Share Price
$2.42
Last synced: 2026-08-25
Market Cap
$152.37M
Change (1 day)
5.22%
Change (1 year)
39.88%
Country
US
Trade Connect Biopharma Holdings Limited (CNTB)

Category

Healthcare
Revenue for Connect Biopharma Holdings Limited (CNTB)
Revenue in Aug 2026 TTM: 0
According to Connect Biopharma Holdings Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Connect Biopharma Holdings Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH